author-photo

Andrew Cakana

Janssen Pharmaceutica
Johnson & Johnson

73

Papers

4345

Citations

Citation Trend

Filter By

Papers (53) Sort By

Journal Conference Others

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

2017 Haematologica
Show All
- Source
- Cite
- Save
Citations (2)
A multicenter phase II study of the efficacy and safety of quisinostat (an HDAC inhibitor) in combination with paclitaxel and carboplatin chemotherapy (CT) in patients (pts) with recurrent platinum resistant high grade serous epithelial ovarian, primarily peritoneal or fallopian tube carcinoma cancer (OC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Prolonged therapy with single-agent bortezomib (btz) in four patients (pts) with relapsed primary systemic AL amyloidosis treated in the CAN2007 phase II study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (18)
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials

2016 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (22)
Phase I dose of oral quisinostat, in combination with gemcitabine (G) and cisplatin (Cis) or paclitaxel (P) and carboplatin (Carbo) in patients (pts) with non-small cell lung cancer or ovarian cancer (OC)

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

2016 Cancer
Show All
- Source
- Cite
- Save
Citations (29)
Economic Burden of Relapsed or Refractory Multiple Myeloma: Results from an International Trial

2015 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis.

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (197)